FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
The hospital in association with ‘We Warriors’ and ‘Dev Bhumi Rakshak Foundation’ organized First Aid and CPR training session for youngsters and volunteers
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated